APO RESEARCH · REPORT
Drugs for Vulvovaginal Candidiasis
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Product & engineering
Understand the product.
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
Selected research
Industry Research
Drugs for Vulvovaginal Candidiasis Industry Research Report 2026
Market perspective
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
Read the full market overview
The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%
Report Scope
This report quantifies the global Drugs for Vulvovaginal Candidiasis market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drugs for Vulvovaginal Candidiasis Market by Company
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Drugs for Vulvovaginal Candidiasis Segment by Type
Cream
Pessary
Other
Drugs for Vulvovaginal Candidiasis Segment by Application
Hospital & Clinic
Pharmacy
Drugs for Vulvovaginal Candidiasis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Vulvovaginal Candidiasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Vulvovaginal Candidiasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Vulvovaginal Candidiasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Drugs for Vulvovaginal Candidiasis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Drugs for Vulvovaginal Candidiasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cream
- Pessary
- Other
Applications
- Hospital & Clinic
- Pharmacy
Companies covered
- Bayer
- Perrigo
- J & J
- Pfizer
- Bristol-Myers Squibb
- Effik
- Teva
- Sanofi
- Cisen Pharmaceutical
- Kingyork Group
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Drugs for Vulvovaginal Candidiasis Market Size (2021-2032)
- 2.2.2 Global Drugs for Vulvovaginal Candidiasis Sales (2021-2032)
- 2.2.3 Global Drugs for Vulvovaginal Candidiasis Market Average Price (2021-2032)
- 2.3 Drugs for Vulvovaginal Candidiasis by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Cream
- 2.3.3 Pessary
- 2.3.4 Other
- 2.4 Drugs for Vulvovaginal Candidiasis by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital & Clinic
- 2.4.3 Pharmacy
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Drugs for Vulvovaginal Candidiasis Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Drugs for Vulvovaginal Candidiasis Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Drugs for Vulvovaginal Candidiasis Revenue of Manufacturers (2021-2026)
- 3.4 Global Drugs for Vulvovaginal Candidiasis Average Price by Manufacturers (2021-2026)
- 3.5 Global Drugs for Vulvovaginal Candidiasis Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Drugs for Vulvovaginal Candidiasis, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Drugs for Vulvovaginal Candidiasis, Product Type & Application
- 3.8 Global Manufacturers of Drugs for Vulvovaginal Candidiasis, Established Date
- 3.9 Global Drugs for Vulvovaginal Candidiasis Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bayer
- 4.1.1 Bayer Company Information
- 4.1.2 Bayer Business Overview
- 4.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bayer Drugs for Vulvovaginal Candidiasis Product Portfolio
- 4.1.5 Bayer Recent Developments
- 4.2 Perrigo
- 4.2.1 Perrigo Company Information
- 4.2.2 Perrigo Business Overview
- 4.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Product Portfolio
- 4.2.5 Perrigo Recent Developments
- 4.3 J & J
- 4.3.1 J & J Company Information
- 4.3.2 J & J Business Overview
- 4.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 J & J Drugs for Vulvovaginal Candidiasis Product Portfolio
- 4.3.5 J & J Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Bristol-Myers Squibb
- 4.5.1 Bristol-Myers Squibb Company Information
- 4.5.2 Bristol-Myers Squibb Business Overview
- 4.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Portfolio
- 4.5.5 Bristol-Myers Squibb Recent Developments
- 4.6 Effik
- 4.6.1 Effik Company Information
- 4.6.2 Effik Business Overview
- 4.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Effik Drugs for Vulvovaginal Candidiasis Product Portfolio
- 4.6.5 Effik Recent Developments
- 4.7 Teva
- 4.7.1 Teva Company Information
- 4.7.2 Teva Business Overview
- 4.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Teva Drugs for Vulvovaginal Candidiasis Product Portfolio
- 4.7.5 Teva Recent Developments
- 4.8 Sanofi
- 4.8.1 Sanofi Company Information
- 4.8.2 Sanofi Business Overview
- 4.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Product Portfolio
- 4.8.5 Sanofi Recent Developments
- 4.9 Cisen Pharmaceutical
- 4.9.1 Cisen Pharmaceutical Company Information
- 4.9.2 Cisen Pharmaceutical Business Overview
- 4.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Portfolio
- 4.9.5 Cisen Pharmaceutical Recent Developments
- 4.10 Kingyork Group
- 4.10.1 Kingyork Group Company Information
- 4.10.2 Kingyork Group Business Overview
- 4.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Product Portfolio
- 4.10.5 Kingyork Group Recent Developments
5 Global Drugs for Vulvovaginal Candidiasis Market Scenario by Region
- 5.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2021-2032
- 5.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2021-2026
- 5.2.2 Global Drugs for Vulvovaginal Candidiasis Sales by Region: 2027-2032
- 5.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2021-2032
- 5.3.1 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2021-2026
- 5.3.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Region: 2027-2032
- 5.4 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
- 5.4.1 North America Drugs for Vulvovaginal Candidiasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2032)
- 5.4.3 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
- 5.5.1 Europe Drugs for Vulvovaginal Candidiasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2032)
- 5.5.3 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
- 5.6.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
- 5.7.1 South America Drugs for Vulvovaginal Candidiasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2032)
- 5.7.3 South America Drugs for Vulvovaginal Candidiasis Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2021-2032)
- 6.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2021-2032)
- 6.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2021-2032)
- 6.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2021-2032)
- 6.3 Global Drugs for Vulvovaginal Candidiasis Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2021-2032)
- 7.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2021-2032)
- 7.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2021-2032)
- 7.2.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2021-2032)
- 7.3 Global Drugs for Vulvovaginal Candidiasis Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Drugs for Vulvovaginal Candidiasis Value Chain Analysis
- 8.1.1 Drugs for Vulvovaginal Candidiasis Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Drugs for Vulvovaginal Candidiasis Production Mode & Process
- 8.2 Drugs for Vulvovaginal Candidiasis Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Drugs for Vulvovaginal Candidiasis Distributors
- 8.2.3 Drugs for Vulvovaginal Candidiasis Customers
9 Global Drugs for Vulvovaginal Candidiasis Analyzing Market Dynamics
- 9.1 Drugs for Vulvovaginal Candidiasis Industry Trends
- 9.2 Drugs for Vulvovaginal Candidiasis Industry Drivers
- 9.3 Drugs for Vulvovaginal Candidiasis Industry Opportunities and Challenges
- 9.4 Drugs for Vulvovaginal Candidiasis Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst